Company intelligence / Profile preview

Orphelion

Ownership: Private
Development stage: Other

Overview

Orphelion is developing new molecules and formulations to address unmet medical needs in animal care. Their lead program, TT001, is a novel small molecule with selective dose-dependent receptor antagonism aimed at pain management. The company also has a program targeting acid reflux in pets. Both programs are currently focused on dogs, with potential expansion to cats and horses. Additional bridging studies are planned where data from rodents or humans exist[1].

Therapeutic areas: GastroenterologyNeurology
Modalities: Small molecule
Industry: Veterinary

Partnerships

No major pharmaceutical or biotech partnerships disclosed

Beyond the preview

Go deeper on Orphelion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orphelion.

Explore the full profile